FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
PBM reform, including spread pricing, AWP setting and/or dispense rate policy, ASP policy, any willing pharmacy laws in Medicare, third party essential medicine testing
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
| STEVEN CHASE WALKER New | Congressman Jodey Arrington |
Trade (domestic/foreign) TRD
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
| STEVEN CHASE WALKER New | Congressman Jodey Arrington |
Medicare/Medicaid MMM
PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty, most favored nations executive order, AWP reform, U.S. manufacturer preferencing, Medicare conditions of participation relating to resiliency standards linked to government reimbursement, 340b reform including PBM-owned 340b pharmacies, Medicare formulary policy and specialty tier reform, generics on generic tiers, Medicaid generics penalty, IRA inflationary penalty, manufacturer discount program
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
| STEVEN CHASE WALKER New | Congressman Jodey Arrington |
Taxation/Internal Revenue Code TAX
BEAT, AMT, U.S. manufacturing incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | Congressman Tom Davis |
| STEVEN CHASE WALKER New | Congressman Jodey Arrington |
Health Issues HCR
Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
Manufacturing MAN
Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
| STEVEN CHASE WALKER | — |
Tariff (miscellaneous tariff bills) TAR
Section 232 investigation into pharmaceuticals and unfair trade practices
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
| STEVEN CHASE WALKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.